Mineralys Therapeutics (Mineralys Therapeutics) Market Cap : $667.77 Mil (As of Jun. 07, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mineralys Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mineralys Therapeutics's share price for the quarter that ended in Mar. 2024 was $12.91. Mineralys Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 49.63 Mil. Therefore, Mineralys Therapeutics's market cap for the quarter that ended in Mar. 2024 was $640.76 Mil.

Mineralys Therapeutics's quarterly market cap declined from Sep. 2023 ($390.91 Mil) to Dec. 2023 ($353.75 Mil) but then increased from Dec. 2023 ($353.75 Mil) to Mar. 2024 ($640.76 Mil).

Mineralys Therapeutics's annual market cap stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($353.75 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mineralys Therapeutics's Enterprise Value for Today is $672.85 Mil.

Mineralys Therapeutics Market Cap Historical Data

The historical data trend for Mineralys Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mineralys Therapeutics Market Cap Chart

Mineralys Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Market Cap

353.75

Mineralys Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Market Cap	Get a 7-Day Free Trial							639.82	696.61	390.91	353.75	640.76

Competitive Comparison of Mineralys Therapeutics's Market Cap

For the Biotechnology subindustry, Mineralys Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mineralys Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's Market Cap falls into.

Mineralys Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Mineralys Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$8.6	*	41.1339
	=	$353.75

Mineralys Therapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )	=	Share Price (Q: Mar. 2024 )	*	Shares Outstanding (EOP) (Q: Mar. 2024 )
	=	$12.91	*	49.633
	=	$640.76

Mineralys Therapeutics (NAS:MLYS) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Mineralys Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Mineralys Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Mineralys Therapeutics (Mineralys Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mineralys Therapeutics Inc (NAS:MLYS) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087

Website

https://mineralystx.com

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Executives

Jon Congleton	director, officer: Chief Executive Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Glenn Sblendorio	director	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
David Malcom Rodman	officer: Chief Medical Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Srinivas Akkaraju	director, 10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Hbm Healthcare Investments (cayman) Ltd.	10 percent owner	GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204
Adam Scott Levy	officer: CFO, Chief Bus. Off. and Secy.	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
Catalys Pacific Fund, Lp	10 percent owner	301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035
Olivier Litzka	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Takeshi Takahashi	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Brian Taylor Slingsby	director, 10 percent owner	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Ra Capital Nexus Fund Iii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Alexander Asam	director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361